Mutations in TP53 and KRAS were detectable on average 20 months and 14 months prior to cancer diagnosis, respectively, but only in 4.6% of patients for TP53 and 1.5% for KRAS. Furthermore, 3% and 0.9% controls that did not develop cancer in over 5 years of follow up were also positive for TP53 and KRAS mutations [116]. The gene discussed is KRAS; the disease is cancer.